Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda to integrate its Ireland subsidiaries
Takeda Pharmaceutical Company has reported that it will integrate its wholly owned subsidiaries Takeda Ireland Limited or TIL and Takeda Pharma Ireland Limited or TPI into a single
Takeda Pharmaceutical Company has reported that it will integrate its wholly owned subsidiaries Takeda Ireland Limited or TIL and Takeda Pharma Ireland Limited or TPI into a single
Canadian biopharmaceutical company MethylGene has reported a net loss of C$6.1m or C$0.17 per share for the first quarter ended March 31, 2009 compared to a net loss
Inhibitex, a biopharmaceutical company, has initiated a Phase II clinical trial with FV-100, its oral antiviral compound in clinical development for the treatment of herpes zoster. The Phase
French molecular diagnostic company Ipsogen has launched the MapQuant Dx HR test in Europe. The MapQuant Dx testing solution has been developed under the Innovation Support Program of
Concert Pharmaceuticals, a clinical stage biotechnology company, has received its first patents from the US Patent and Trademark Office. These patents relate to specific compounds derived from Concert’s
ABMC chief executive officer, Stan Cipkowski, stated, “Our story hasn’t changed much since March when we reported results for our 2008 fiscal year. We continue to experience decreased
Gross profit from continuing operations was $2.8 million or 56% during the first quarter of 2009 compared to $3.6 million or 58% during the comparable period of 2008.
The Society of Chemical Manufacturers and Affiliates (SOCMA) has acquired ChemAlliance, an online compliance assistance centre formerly funded by the US Environmental Protection Agency (EPA) and designed to
Bisphenol, commonly known as BPA and an important monomer for plastic additives, has been banned by Minnesota from being used in baby bottles and sippy cups and food
Takeda Pharmaceutical Company and its wholly-owned UK-based subsidiary for overseeing pan-European sales and marketing, Takeda Pharmaceutical Europe have reported that they plan to start their own wholly owned